U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07474792) titled 'Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis' on March 11.

Brief Summary: This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condition: Plaque Psoriasis

Intervention: DRUG: ORKA-002

ORKA-002 administered by subcutaneous (SC) injection

OTHER: Placebo

Placebo administered by subcutaneous (SC) injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Oruka Therapeutics, Inc....